Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drug enters final testing phase

NCT ID NCT07394114

Summary

This study is testing whether a new injectable medication called HDM1005 can help control blood sugar in people with type 2 diabetes who haven't yet started other diabetes drugs. About 240 participants will receive either the real medication or a placebo injection for 36 weeks, with everyone eventually getting the chance to try HDM1005. Researchers will measure changes in long-term blood sugar levels (HbA1c), body weight, and safety over 60 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.